Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers

被引：3
|
作者：
Kato, Renpei [1 ]
Obara, Wataru [1 ]
机构：
[1] Iwate Med Univ, Dept Urol, Morioka, Iwate, Japan
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2022年 / 22卷 / 07期
关键词：
anti-PD-1/PD-L1; therapy; biomarker; renal cell carcinoma; PD-L1; expression; peripheral blood biomarkers; CIRCULATING TUMOR DNA; CHECKPOINT; EXPRESSION;
D O I：
10.1080/14737140.2022.2087631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：667 / 669
页数：3
相关论文
共 50 条
  • [41] Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
    Spirina, Liudmila
    Yurmazov, Zahar
    Usynin, Evgeny
    Kondakova, Irina
    Ladutko, Ekaterine
    Choynzonov, Evgeny
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2021, 43 (02) : 1072 - 1080
  • [42] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [43] Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
    Sui, Hongshu
    Ma, Ningxia
    Wang, Ying
    Li, Hui
    Liu, Xiaoming
    Su, Yanping
    Yang, Jiali
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [44] The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma
    McKay, Rana R.
    Bosse, Dominick
    Xie, Wanling
    Wankowicz, Stephanie A. M.
    Flaifel, Abdallah
    Brandao, Raphael
    Lalani, Aly-Khan A.
    Martini, Dylan J.
    Wei, Xiao X.
    Braun, David A.
    Van Allen, Eliezer
    Castellano, Daniel
    De Velasco, Guillermo
    Wells, J. Connor
    Heng, Daniel Y.
    Fay, Andre P.
    Schutz, Fabio A.
    Hsu, JoAnn
    Pal, Sumanta K.
    Lee, Jae Lyun
    Hsieh, James J.
    Harshman, Lauren C.
    Signoretti, Sabina
    Motzer, Robert J.
    Feldman, Darren
    Choueiri, Toni K.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (07) : 758 - 765
  • [45] New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
    Chen, Cheng
    Huang, Jian-An
    EUROPEAN JOURNAL OF INFLAMMATION, 2016, 14 (01) : 61 - 65
  • [46] The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
    Yoon, Seung Bae
    Woo, Sang Myung
    Chun, Jung Won
    Kim, Dong Uk
    Kim, Jaihwan
    Park, Joo Kyung
    So, Hoonsub
    Chung, Moon Jae
    Cho, In Rae
    Heo, Jun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [47] TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
    Yi, Ming
    Li, Tianye
    Niu, Mengke
    Wu, Yuze
    Zhao, Zhenyu
    Wu, Kongming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [49] Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
    Weinstock, Matthew
    McDermott, David
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (06) : 365 - 377
  • [50] Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
    Yang, Yuanyuan
    Wang, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
12345